Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein… (NCT04140448) | Clinical Trial Compass
UnknownNot Applicable
Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
China60 participantsStarted 2023-10-09
Plain-language summary
This study mainly observed the ischemic index and vascular leakage index changes on ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these changes correlated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female aged 18 years or older
✓. Macular edema secondary to CRVO,BRVO or HRVO
✓. Duration of RVO not more than 4 months
✓. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) completely resolved (normalization of visual acuity and fundus examination) and who have experienced a recurrence of RVO are also considered naive
✓. Patient who agrees to participate in the study and who has given his/her written, informed consent
Exclusion criteria
✕. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
✕. Active or suspected ocular or periocular infection
✕. Active severe intraocular inflammation
✕. RVO complicated with neovascularization
✕. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye
✕. Patient already included in the study for the treatment of the fellow eye
What they're measuring
1
Change in vascular leakage index in different retinal area
Timeframe: Baseline and 1,2,3,4,6,9 and 12 months
2
Change in non-perfused areas in different retinal area